Literature DB >> 11986260

Inclusion fluorescent-antibody test as a screening assay for detection of antibodies to Chlamydia pneumoniae.

Olga Tapia1, Anatoly Slepenkin, Evgueni Sevrioukov, Kathi Hamor, Luis M de la Maza, Ellena M Peterson.   

Abstract

A study was conducted to determine the ability of the inclusion immunofluorescence assay (inclusion IFA) to act as a screening test to detect samples with antibodies to Chlamydia pneumoniae; microimmunofluorescence (MIF) was used as the "gold standard." In addition, the inclusion IFA was compared using HEp-2 cells infected with either C. pneumoniae CM-1 or Chlamydia trachomatis serovar E. A total of 331 serum samples representing a range of MIF titers were evaluated. The sensitivities of the inclusion IFA for detecting samples with C. pneumoniae MIF titers of > or = 16 were 96.9 and 74.8% with C. pneumoniae- and C. trachomatis-infected cells, respectively. For samples with an elevated C. pneumoniae MIF titer of > or = 512, the sensitivities of the C. pneumoniae- and C. trachomatis-based inclusion IFA were 97.0 and 8.8%, respectively. These results suggest that the inclusion IFA is not a genus-specific test, as evidenced by the failure of the C. trachomatis-infected cells to detect a significant number of samples with C. pneumoniae antibodies. Samples that had elevated C. pneumoniae inclusion IFA and MIF titers but that were found negative (titer, <16) by the C. trachomatis inclusion IFA were further tested by an in vitro neutralization assay for functional antibodies that might not have been detected by the serological assays. The in vitro neutralization results corroborated the serological results in that all seven sera tested had a neutralization titer for C. pneumoniae (range, 20 to 225), while all but one failed to have any effect on the infectivity of C. trachomatis serovar E. While the C. pneumoniae inclusion IFA had a high sensitivity for detecting chlamydial antibodies, depending on whether it was used as a screening test for detecting samples with low (> or = 16) or elevated (> or = 512) MIF titers, its specificity ranged from 53.4 to 77.1%. In conclusion, the inclusion IFA with C. pneumoniae-infected cells was best suited as a sensitive screening test for identifying specimens with elevated MIF titers (those associated with a possible acute infection with C. pneumoniae).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986260      PMCID: PMC119991          DOI: 10.1128/cdli.9.3.562-567.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  24 in total

1.  Comparison of two commercial microimmunofluorescence kits and an enzyme immunoassay kit for detection of serum immunoglobulin G antibodies to Chlamydia pneumoniae.

Authors:  T O Messmer; J Martinez; F Hassouna; E R Zell; W Harris; S Dowell; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results.

Authors:  R W Peeling; S P Wang; J T Grayston; F Blasi; J Boman; A Clad; H Freidank; C A Gaydos; J Gnarpe; T Hagiwara; R B Jones; J Orfila; K Persson; M Puolakkainen; P Saikku; J Schachter
Journal:  J Infect Dis       Date:  2000-06       Impact factor: 5.226

3.  Potential relevance of Chlamydia pneumoniae surface proteins to an effective vaccine.

Authors:  G Christiansen; A S Pedersen; K Hjerno; B Vandahl; S Birkelund
Journal:  J Infect Dis       Date:  2000-06       Impact factor: 5.226

4.  Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS.

Authors:  J Boman; P M Roblin; P Sundström; M Sandström; M R Hammerschlag
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

5.  Is Chlamydia pneumoniae present in brain lesions of patients with multiple sclerosis?

Authors:  M R Hammerschlag; Z Ke; F Lu; P Roblin; J Boman; B Kalman
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

6.  Microbiology. Do chronic diseases have an infectious root?

Authors:  C Zimmer
Journal:  Science       Date:  2001-09-14       Impact factor: 47.728

Review 7.  Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).

Authors:  S F Dowell; R W Peeling; J Boman; G M Carlone; B S Fields; J Guarner; M R Hammerschlag; L A Jackson; C C Kuo; M Maass; T O Messmer; D F Talkington; M L Tondella; S R Zaki
Journal:  Clin Infect Dis       Date:  2001-07-20       Impact factor: 9.079

8.  Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test.

Authors:  S P Wang; J T Grayston
Journal:  Am J Ophthalmol       Date:  1970-09       Impact factor: 5.258

Review 9.  WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics.

Authors:  M Dunne
Journal:  Am Heart J       Date:  1999-11       Impact factor: 4.749

10.  Chlamydia pneumoniae major outer membrane protein is a surface-exposed antigen that elicits antibodies primarily directed against conformation-dependent determinants.

Authors:  K Wolf; E Fischer; D Mead; G Zhong; R Peeling; B Whitmire; H D Caldwell
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.